Since NAFLD/NASH progression is associated with systemic inflammation [20], the plasma levels of the three pro-inflammatory markers IL-6, TNF-α, and CRP were evaluated. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.